Oncology

Strategic Objectives

To contribute to the development of programmes which optimise a personalised approach to the treatment of breast cancer patients, taking into account the specific characteristics of both the tumour and the cancer patient.

Clinical research: To continue and promote the creation of clinical trials to develop new diagnostic and therapeutic strategies, and more specifically studies into new drugs.

Developing new programmes for translational research, either as independent studies or as studies in parallel to or associated with clinical trials. The goal is to develop and implement new molecular techniques that may be diagnostically and predictively relevant to the optimisation of treatments suitable to each molecular subtype.

Development of studies in the areas of epidemiology and the follow-up of breast cancer patients.

Main lines of research

Study of the presence and prognostic significance of status heterogeneity in the receptors between the primary tumour and the synchronous lymph node metastasis in hormone receptor-positive breast cancers.

Circulating tumoural stem cells in breast cancer.

Comparison between the clinical-pathological features of interval breast cancers (IC) and those detected in the programmed screening among the participants in the Basque Health Service’s breast cancer detection programme.

Use of next-generation sequencing technology to analyse genetic differences between the primary tumour and metastatic sites.

Identification and validation of circulating miRNA/RNA as non-invasive markers for breast cancer.

Use of shRNA/miRNA coding viral libraries in order to identify factors of resistance to drugs and new therapies in breast cancer.

Team Members

Name Surname

Center

E-mail

Nerea Ancizar Lizarraga

Donostialdea IHO

nerea.ancizarlizarraga@osakidetza.eus

María Cristina Churruca Galaz

Donostialdea IHO

cristinamaria.churrucagalaz@osakidetza.eus

María Díez Zubizarreta

Donostialdea IHO

maria.diez@biodonostia.org

Marta Fernández Calleja

Donostialdea IHO

mfernand@chdo.osakidetza.eus

Elena Guimón Olaizola

Donostialdea IHO

elena.guimonolaizola@osakidetza.eus

Ana Paisán Ruiz

Donostialdea IHO

ana.paisanruiz@osakidetza.eus

Marta Rezola Bajineta

Donostialdea IHO

Jose María Urraca De La Serna

Donostialdea IHO

josemaria.urracadelaserna@osakidetza.eus

Ander Urruticoechea Ribate

Onkologikoa Fundazioa

anderu@onkologikoa.org

Scientific Output

Originals

Published:
10 / 17

Early stage ovarian cancer clinical behavior according to FIGO 2014 Staging changes with a focus on IC subtype: data from prospective GEICO registry.